1. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
- Author
-
Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, and Maly DJ
- Subjects
- Administration, Oral, Animals, Antiprotozoal Agents administration & dosage, Antiprotozoal Agents chemistry, Disease Models, Animal, Dogs, Dose-Response Relationship, Drug, Ether-A-Go-Go Potassium Channels metabolism, Female, Haplorhini, Mice, Mice, Inbred BALB C, Molecular Structure, Parasitic Sensitivity Tests, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors chemistry, Rats, Rats, Sprague-Dawley, Structure-Activity Relationship, Toxoplasma enzymology, Toxoplasmosis metabolism, Antiprotozoal Agents pharmacology, Central Nervous System drug effects, Drug Design, Ether-A-Go-Go Potassium Channels antagonists & inhibitors, Protein Kinase Inhibitors pharmacology, Protein Kinases metabolism, Toxoplasma drug effects, Toxoplasmosis drug therapy
- Abstract
New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) that possesses antitoxoplasmosis activity in vitro and in vivo. Unfortunately, 1 has potent human ether-a-go-go-related gene (hERG) inhibitory activity, associated with long Q-T syndrome, and consequently presents a cardiotoxicity risk. Here, we describe the identification of an optimized TgCDPK1 inhibitor 32, which does not have a hERG liability and possesses a favorable pharmacokinetic profile in small and large animals. 32 is CNS-penetrant and highly effective in acute and latent mouse models of T. gondii infection, significantly reducing the amount of parasite in the brain, spleen, and peritoneal fluid and reducing brain cysts by >85%. These properties make 32 a promising lead for the development of a new antitoxoplasmosis therapy., Competing Interests: Notes The authors declare the following competing financial interest: Gail Freiberg, Kennan Marsh, and Dale Kempf are employees of Abbvie.
- Published
- 2016
- Full Text
- View/download PDF